The Annals of pharmacotherapy
-
Randomized Controlled Trial Clinical Trial
Mexiletine in the symptomatic treatment of diabetic peripheral neuropathy.
To evaluate the efficacy and safety of mexiletine in the symptomatic treatment of diabetic peripheral neuropathy (DPN). ⋯ Because of conflicting reports of mexiletine's efficacy in the treatment of symptomatic DPN, this drug should be reserved for patients unresponsive or intolerant to standard therapy, without evidence of heart disease, and with sensations of burning heat, formication, or stabbing pain.
-
Comparative Study
Evaluation of drug interaction document citation in nine on-line bibliographic databases.
To compare nine on-line bibliographic databases to obtain bibliographic references on specific drug interactions. ⋯ To obtain bibliographic references on drug interactions, the first step should be to search MEDLINE or TOXLINE; the second step, for completeness, should be to search EMBASE.
-
To report a case of rhabdomyolysis associated with epsilon-aminocaproic acid (epsilon-ACA). ⋯ Long-term therapy with high-dose epsilon-ACA may produce muscle weakness or rhabdomyolysis. Patients who require long-term, high-dose epsilon-ACA therapy should be monitored for myoglobinuria and changes in serum CK, LDH, and AST, for myoglobinemia, for decreases in muscle strength, and/or for myalgia. Significant changes in these parameters compared with baseline values should suggest a need to discontinue epsilon-ACA therapy.